[1,2] The treatment was tested in a large 18-month clinical study in patients with mild cognitive impairment (MCI) and mild dementia due to early AD. Even though you cannot stop AD from getting ...

Several clinical trials, some of which remain unpublished, have attempted to determine whether treatment with cholinesterase inhibitors (ChEIs) can slow or prevent the conversion of MCI to ...

In a recent study, lean muscle mass appeared to be a protective factor against the development of Alzheimer's disease.

Pending approval for Phenserine in Alzheimer's patients, he says Axonyx does intend to study the drug further as a treatment for mild cognitive impairment (MCI ... work in the area of the ...

Shares of Sage Therapeutics, Inc. SAGE were down 4.3% on Oct. 8 after the company announced disappointing top-line data from ...

Moreover, some patient families may need to stay long-term in the area while a patient receives treatment; you can help the families find cheap accommodations. Many patients may not be able to go home ...

Shimadzu Corporation, Eisai Co., Ltd., Oita University, and Usuki City Medical Association have demonstrated the utility of blood biomarkers in predicting the accumulation of amyloid beta (Aβ)(1) in ...

Alzheimer's treatment for adults with early symptomatic Alzheimer's disease (AD), which includes people with mild cognitive impairment (MCI) as well as people with the mild dementia stage of AD ...

The revision follows the announcement that Sage's drug dalzanemdor did not meet the primary goal in the Phase 2 LIGHTWAVE study, which evaluated the treatment in patients with Alzheimer's ...